Finizio

TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium

Retrieved on: 
Thursday, April 8, 2021
General Health, Women, Consumer, Health, Pharmaceutical, Software, Operating systems, Computing, Universal Windows Platform apps, Finizio, Facebook, Twitter, BIJUVA, Theramex, TherapeuticsMD, Inc.

A decentralized procedure (DCP) for the regulatory approval of BIJUVA in several European countries was completed in February.

Key Points: 
  • A decentralized procedure (DCP) for the regulatory approval of BIJUVA in several European countries was completed in February.
  • Following this each country undertakes a national process which includes approvals for labeling and other country specific requirements.
  • The approval of BIJUVE in the UK and BIJUVA in Belgium marks a significant accomplishment by Theramex that offers a new treatment option to post-menopausal women, said Robert Finizio, Chief Executive Officer of TherapeuticsMD.
  • To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

TherapeuticsMD Provides COVID-19-Related Business Update

Retrieved on: 
Thursday, March 26, 2020
Health, Consumer, Women, Baby, Maternity, Pharmaceutical, Biotechnology, Operating systems, Software, Articles, Universal Windows Platform apps, Animal virology, Coronaviridae, Coronavirus, Pandemic, Facebook, Finizio, Medical scribe, Twitter

TherapeuticsMD, Inc. (NASDAQ: TXMD) (TherapeuticsMD or the Company), an innovative, leading womens healthcare company, today provided an update on its operations in response to the continued spread of COVID-19 (coronavirus) pandemic.

Key Points: 
  • TherapeuticsMD, Inc. (NASDAQ: TXMD) (TherapeuticsMD or the Company), an innovative, leading womens healthcare company, today provided an update on its operations in response to the continued spread of COVID-19 (coronavirus) pandemic.
  • The health and safety of our employees, patients, prescribers, and community are paramount at this time, said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD.
  • TherapeuticsMD is implementing measures to initially cut or defer more than $30 million in annual spending.
  • To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Attorney Jamie Finizio Bascombe Launches The Law Offices of Jamie Finizio Bascombe, P.A.

Retrieved on: 
Thursday, February 27, 2020
Geography of Florida, Florida, Finizio, Bascombe, Fort Lauderdale, Florida

The Law Offices of Jamie Finizio Bascombe, P.A.

Key Points: 
  • The Law Offices of Jamie Finizio Bascombe, P.A.
  • Jamie's work includes aviation accident cases, representing victims of various international air disasters including crashes throughout Central and South America.
  • Jamie has received numerous awards fromBarassociations, voted on by her own colleagues, and for her advocacy and legal work, fromthe communitiesthatshe serves.
  • The Law Offices of Jamie Finizio Bascombe, P. A. is located at 107 SE 10thSt., Fort Lauderdale, Florida 33316.

TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States

Retrieved on: 
Friday, June 7, 2019
Women, Health, Pharmaceutical, Consumer, Expense, Intellectual property law, Patent law, Royalty payment, License, Finizio

Theramex will have exclusive commercialization rights for BIJUVA and IMVEXXY outside the U.S., excluding Canada and Israel, for which TherapeuticsMD has licensed BIJUVA and IMVEXXY to Knight Therapeutics.

Key Points: 
  • Theramex will have exclusive commercialization rights for BIJUVA and IMVEXXY outside the U.S., excluding Canada and Israel, for which TherapeuticsMD has licensed BIJUVA and IMVEXXY to Knight Therapeutics.
  • Under the terms of the license and supply agreement, Theramex will pay TherapeuticsMD EUR 14 million in cash as an upfront fee.
  • TherapeuticsMD is also entitled to receive royalty payments on net sales of BIJUVA and IMVEXXY in the licensed territories.
  • "We are very pleased to announce our partnership with Theramex to bring BIJUVA and IMVEXXY to women outside of the United States, said Robert G. Finizio, CEO of TherapeuticsMD.